newsfilter
← Latest News
GlobeNewswire·

Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results

Reported interim results for Phase 1 trial for ABS-101 (anti-TL1A) On track to initiate Ph1/2a trial for ABS-201 (anti-PRLR for androgenetic alopecia) in December; hosting KOL seminar on December 11 Expanding ABS-201